Technical Analysis for NBIX - Neurocrine Biosciences, Inc.

Grade Last Price % Change Price Change
grade A 131.12 4.00% 5.04
NBIX closed up 4.0 percent on Tuesday, July 14, 2020, on 1.13 times normal volume.
Earnings due: Jul 27
*** please verify all earnings dates ***

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical NBIX trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
180 Bullish Setup Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Multiple of Ten Bullish Other 0.00%
MACD Bearish Signal Line Cross Bearish 4.00%
Multiple of Ten Bearish Other 4.00%
Outside Day Range Expansion 4.00%
Slingshot Bullish Bullish Swing Setup 1.10%
Multiple of Ten Bearish Other 1.10%
MACD Bullish Signal Line Cross Bullish -0.33%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. It develops drugs for endometriosis, tardive dyskinesia, uterine fibroids, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. The company's products in clinical development include Elagolix, a Phase III drug for endometriosis; Vesicular Monoamine Transporter 2 Inhibitor (VMAT2), a Phase II drug for movement disorders; CRF2 Peptide Agonist, a Phase II drug for cardiovascular diseases; CRF1 Antagonist, a Phase II drug for stress-related disorders; and Elagolix, a Phase II drug for uterine fibroids. Its research programs comprise G Protein-Coupled Receptor 119 (GPR119) for type II diabetes; VMAT2 for schizophrenia; gonadotropin-releasing hormone (GnRH) Antagonists for men's and women's health, and oncology; Antiepileptic Drugs for epilepsy, essential tremor, and pain; and G Protein-Coupled Receptors for other conditions. The company has collaborations with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Boehringer Ingelheim International GmbH to research, develop, and commercialize small molecule GPR119 agonists for the treatment of Type II diabetes and other indications; and Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize indiplon in Japan. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Chemistry Pain Diabetes Disorders Schizophrenia Hormones Alcohols Cardiovascular Diseases Epilepsy Movement Disorders Ethers Ii Diabetes Gnrh Antagonists Pyrimidines Uterine Fibroids Endometriosis Gonadotropin Releasing Hormone Antagonist Insomnia

Is NBIX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 136.265
52 Week Low 72.14
Average Volume 908,518
200-Day Moving Average 105.32
50-Day Moving Average 120.39
20-Day Moving Average 126.51
10-Day Moving Average 127.74
Average True Range 4.90
ADX 22.39
+DI 23.66
-DI 18.60
Chandelier Exit (Long, 3 ATRs ) 121.57
Chandelier Exit (Short, 3 ATRs ) 126.32
Upper Bollinger Band 133.78
Lower Bollinger Band 119.23
Percent B (%b) 0.82
BandWidth 11.50
MACD Line 2.98
MACD Signal Line 3.07
MACD Histogram -0.0883
Fundamentals Value
Market Cap 11.56 Billion
Num Shares 88.2 Million
EPS -2.52
Price-to-Earnings (P/E) Ratio -52.03
Price-to-Sales 826.51
Price-to-Book 15.16
PEG Ratio 1.78
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 142.93
Resistance 3 (R3) 141.66 136.47 140.96
Resistance 2 (R2) 136.47 133.46 137.10 140.30
Resistance 1 (R1) 133.79 131.60 135.13 135.06 139.65
Pivot Point 128.60 128.60 129.27 129.23 128.60
Support 1 (S1) 125.92 125.59 127.26 127.19 122.59
Support 2 (S2) 120.73 123.73 121.36 121.94
Support 3 (S3) 118.05 120.73 121.28
Support 4 (S4) 119.32